Biological Activity of a 4-Hydroxy-Furanyl-Benzamide Derivative on Heart Failure.

IF 1.7 Q3 PHARMACOLOGY & PHARMACY

Drug Research Pub Date : 2023-03-01 DOI:10.1055/a-1855-1412

Figueroa-Valverde Lauro, Rosas-Nexticapa Marcela, López-Ramos Maria, Alvarez-Ramirez Magdalena, Mateu-Armad Maria Virginia, Díaz-Cedillo Francisco, Cervantes-Ortega Catalina, Melgarejo-Guutierrez Montserrat

{"title":"Biological Activity of a 4-Hydroxy-Furanyl-Benzamide Derivative on Heart Failure.","authors":"Figueroa-Valverde Lauro, Rosas-Nexticapa Marcela, López-Ramos Maria, Alvarez-Ramirez Magdalena, Mateu-Armad Maria Virginia, Díaz-Cedillo Francisco, Cervantes-Ortega Catalina, Melgarejo-Guutierrez Montserrat","doi":"10.1055/a-1855-1412","DOIUrl":null,"url":null,"abstract":"Abstract Background There are studies that suggest that some benzamide derivatives may exert effects on heart failure; however, their molecular mechanism is not very clear. Objective The aim of this research was to evaluate the biological activity of a 4-hydroxy-furanyl-benzamide derivative against heart failure translated as area infarct. Methods Biological activity produced by 4-hydroxy-furanyl-benzamide derivative against heart failure was determinate using an ischemia-reperfusion injury model. In addition, the effects exerted by the 4-hydroxy-furanyl-benzamide derivative on left ventricular pressure (LVP) was evaluated in the absence or presence of some drugs such as yohimbine, butaxamine, methoctramine and L-NAME using a model of rat heart isolated. Results The results showed that 4-hydroxy-furanyl-benzamide derivative decrease both infarct area and LVP. However, the effect produced by 4-hydroxy-furanyl-benzamide derivative on LVP was inhibited in the presence of both methoctramine and L-NAME. Conclusions All these data suggest that biological activity produced by 4-hydroxy-furanyl-benzamide derivative on left ventricular pressure is through of both M 2 -muscarinic receptor and nitric oxide synthase enzyme activation. It is important to mention that this phenomenon results as a decrease of both infarct area and heart failure.","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":"73 3","pages":"175-183"},"PeriodicalIF":1.7000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-1855-1412","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract Background There are studies that suggest that some benzamide derivatives may exert effects on heart failure; however, their molecular mechanism is not very clear. Objective The aim of this research was to evaluate the biological activity of a 4-hydroxy-furanyl-benzamide derivative against heart failure translated as area infarct. Methods Biological activity produced by 4-hydroxy-furanyl-benzamide derivative against heart failure was determinate using an ischemia-reperfusion injury model. In addition, the effects exerted by the 4-hydroxy-furanyl-benzamide derivative on left ventricular pressure (LVP) was evaluated in the absence or presence of some drugs such as yohimbine, butaxamine, methoctramine and L-NAME using a model of rat heart isolated. Results The results showed that 4-hydroxy-furanyl-benzamide derivative decrease both infarct area and LVP. However, the effect produced by 4-hydroxy-furanyl-benzamide derivative on LVP was inhibited in the presence of both methoctramine and L-NAME. Conclusions All these data suggest that biological activity produced by 4-hydroxy-furanyl-benzamide derivative on left ventricular pressure is through of both M 2 -muscarinic receptor and nitric oxide synthase enzyme activation. It is important to mention that this phenomenon results as a decrease of both infarct area and heart failure.

查看原文本刊更多论文

4-羟基呋喃苯酰胺衍生物对心力衰竭的生物活性。

背景:有研究表明，一些苯甲酰胺衍生物可能对心力衰竭有影响;然而，它们的分子机制尚不清楚。目的:评价一种4-羟基呋喃苯甲酰胺衍生物对局部梗死性心力衰竭的生物活性。方法:采用缺血再灌注损伤模型测定4-羟基呋喃苯甲酰胺衍生物对心力衰竭的生物活性。此外，采用离体大鼠心脏模型，在育亨宾、丁他明、甲氧曲明、L-NAME等药物不存在或不存在的情况下，评价4-羟基呋喃苄胺衍生物对左心室压(LVP)的影响。结果:4-羟基呋喃苯甲酰胺衍生物可降低梗死面积和LVP。而4-羟基呋喃苄酰胺衍生物在甲氧苄胺和L-NAME的存在下对LVP的影响被抑制。结论:4-羟基呋喃苯甲酰胺衍生物对左室压的生物活性是通过m2 -毒蕈碱受体和一氧化氮合酶激活两种途径产生的。值得一提的是，这种现象的结果是梗死面积和心力衰竭的减少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Research PHARMACOLOGY & PHARMACY-

CiteScore

3.50

自引率

0.00%

发文量

期刊介绍： Drug Research (formerly Arzneimittelforschung) is an international peer-reviewed journal with expedited processing times presenting the very latest research results related to novel and established drug molecules and the evaluation of new drug development. A key focus of the publication is translational medicine and the application of biological discoveries in the development of drugs for use in the clinical environment. Articles and experimental data from across the field of drug research address not only the issue of drug discovery, but also the mathematical and statistical methods for evaluating results from industrial investigations and clinical trials. Publishing twelve times a year, Drug Research includes original research articles as well as reviews, commentaries and short communications in the following areas: analytics applied to clinical trials chemistry and biochemistry clinical and experimental pharmacology drug interactions efficacy testing pharmacodynamics pharmacokinetics teratology toxicology.